Efficient CRISPR/Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators

Le, T.A.; Chu, V.T.; Lino, A.C.; Schrezenmeier, E.; Kressler, C.; Hamo, D.; Rajewsky, K.; Dörner, T.; Dang, V.D.

Efficient CRISPR/Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 3MB
	Other (Supplemental Information) 4MB

Item Type:	Article
Title:	Efficient CRISPR/Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators
Creators Name:	Le, T.A., Chu, V.T., Lino, A.C., Schrezenmeier, E., Kressler, C., Hamo, D., Rajewsky, K., Dörner, T. and Dang, V.D.
Abstract:	Human B lymphocytes are attractive targets for immunotherapies in autoantibody-mediated diseases. Gene editing technologies could provide a powerful tool to determine gene regulatory networks regulating B cell differentiation into plasma cells, and identify novel therapeutic targets for prevention and treatment of autoimmune disorders. Here, we describe a new approach that uses CRISPR/Cas9 technology to target genes in primary human B cells in vitro for identifying plasma cell regulators. We found that sgRNA and Cas9 components can be efficiently delivered into primary human B cells through RD114-pseudotyped retroviral vectors. Using this system, we achieved approximate 80% of gene knockout efficiency. We disrupted expression of a triad of transcription factors, IRF4, PRDM1 and XBP1, and showed that human B cell survival and plasma cell differentiation are severely impaired. Specifically, that IRF4, PRDM1 and XBP1 are expressed at different stages during plasma cell differentiation, IRF4, PRDM1 and XBP1-targeted cells fail to progress to the pre-PB, PC state and PC survival, respectively. Our method opens a new avenue to study gene functions in primary human B cells and identify novel plasma cell regulators for therapeutic applications.
Keywords:	CRISPR/Cas9, Primary Human B Cells, B Cell Differentiation, Plasmablasts, Plasma Cells, Plasma Cell Regulators, Knockout, IRF4, PRDM1, XBP1
Source:	Molecular Therapy - Nucleic Acids
ISSN:	2162-2531
Publisher:	Nature Publishing Group
Volume:	30
Page Range:	621-632
Date:	13 December 2022
Official Publication:	https://doi.org/10.1016/j.omtn.2022.11.016
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year